Exact Mass: 471.3137
Exact Mass Matches: 471.3137
Found 445 metabolites which its exact mass value is equals to given mass value 471.3137
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Terfenadine
Terfenadine is only found in individuals that have used or taken this drug. In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].
Cervonyl carnitine
Cervonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Cervonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
(10E,15Z)-9,12,13-Trihydroxyoctadeca-10,15-dienoylcarnitine
(10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoylcarnitine is an acylcarnitine. More specifically, it is an (10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoylcarnitine
(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Retronecine 2S-hydroxy-2S-(1S-hydroxyethyl)-2S-[(1S-hydroxyethyl)-4-methylpentanoyl]-4-methylpentanoyl ester
N-(1,4-Dihydroxy-1,2,3,4-tetrahydronaphthyl)-propyl-N-diphenylmethyl-N-3,3-dimethylbutylamine
terfenadine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].
Sipeimine, 3-Ac
Origin: Plant; SubCategory_DNP: Steroidal alkaloids, Cevanine alkaloids
Ala Ile Ile Arg
Ala Ile Leu Arg
Ala Ile Arg Ile
Ala Ile Arg Leu
Ala Leu Ile Arg
Ala Leu Leu Arg
Ala Leu Arg Ile
Ala Leu Arg Leu
Ala Arg Ile Ile
Ala Arg Ile Leu
Ala Arg Leu Ile
Ala Arg Leu Leu
Asp Ile Lys Pro
Asp Ile Pro Lys
Asp Lys Ile Pro
Asp Lys Leu Pro
Asp Lys Pro Ile
Asp Lys Pro Leu
Asp Leu Lys Pro
Asp Leu Pro Lys
Asp Pro Ile Lys
Asp Pro Lys Ile
Asp Pro Lys Leu
Asp Pro Leu Lys
Glu Lys Pro Val
Glu Lys Val Pro
Glu Pro Lys Val
Glu Pro Val Lys
Glu Val Lys Pro
Glu Val Pro Lys
Ile Ala Ile Arg
Ile Ala Leu Arg
Ile Ala Arg Ile
Ile Ala Arg Leu
Ile Asp Lys Pro
Ile Asp Pro Lys
Ile Ile Ala Arg
Ile Ile Ile Asn
Ile Ile Lys Val
Ile Ile Leu Asn
Ile Ile Asn Ile
Ile Ile Asn Leu
Ile Ile Gln Val
Ile Ile Arg Ala
Ile Ile Val Lys
Ile Ile Val Gln
Ile Lys Asp Pro
Ile Lys Ile Val
Ile Lys Leu Val
Ile Lys Pro Asp
Ile Lys Val Ile
Ile Lys Val Leu
Ile Leu Ala Arg
Ile Leu Ile Asn
Ile Leu Lys Val
Ile Leu Leu Asn
Ile Leu Asn Ile
Ile Leu Asn Leu
Ile Leu Gln Val
Ile Leu Arg Ala
Ile Leu Val Lys
Ile Leu Val Gln
Ile Asn Ile Ile
Ile Asn Ile Leu
Ile Asn Leu Ile
Ile Asn Leu Leu
Ile Pro Asp Lys
Ile Pro Lys Asp
Ile Pro Arg Ser
Ile Pro Ser Arg
Ile Gln Ile Val
Ile Gln Leu Val
Ile Gln Val Ile
Ile Gln Val Leu
Ile Arg Ala Ile
Ile Arg Ala Leu
Ile Arg Ile Ala
Ile Arg Leu Ala
Ile Arg Pro Ser
Ile Arg Ser Pro
Ile Ser Pro Arg
Ile Ser Arg Pro
Ile Val Ile Lys
Ile Val Ile Gln
Ile Val Lys Ile
Ile Val Lys Leu
Ile Val Leu Lys
Ile Val Leu Gln
Ile Val Gln Ile
Ile Val Gln Leu
Lys Asp Ile Pro
Lys Asp Leu Pro
Lys Asp Pro Ile
Lys Asp Pro Leu
Lys Glu Pro Val
Lys Glu Val Pro
Lys Ile Asp Pro
Lys Ile Ile Val
Lys Ile Leu Val
Lys Ile Pro Asp
Lys Ile Val Ile
Lys Ile Val Leu
Lys Leu Asp Pro
Lys Leu Ile Val
Lys Leu Leu Val
Lys Leu Pro Asp
Lys Leu Val Ile
Lys Leu Val Leu
Lys Pro Asp Ile
Lys Pro Asp Leu
Lys Pro Glu Val
Lys Pro Ile Asp
Lys Pro Leu Asp
Lys Pro Val Glu
Lys Val Glu Pro
Lys Val Ile Ile
Lys Val Ile Leu
Lys Val Leu Ile
Lys Val Leu Leu
Lys Val Pro Glu
Leu Ala Ile Arg
Leu Ala Leu Arg
Leu Ala Arg Ile
Leu Ala Arg Leu
Leu Asp Lys Pro
Leu Asp Pro Lys
Leu Ile Ala Arg
Leu Ile Ile Asn
Leu Ile Lys Val
Leu Ile Leu Asn
Leu Ile Asn Ile
Leu Ile Asn Leu
Leu Ile Gln Val
Leu Ile Arg Ala
Leu Ile Val Lys
Leu Ile Val Gln
Leu Lys Asp Pro
Leu Lys Ile Val
Leu Lys Leu Val
Leu Lys Pro Asp
Leu Lys Val Ile
Leu Lys Val Leu
Leu Leu Ala Arg
Leu Leu Ile Asn
Leu Leu Lys Val
Leu Leu Leu Asn
Leu Leu Asn Ile
Leu Leu Asn Leu
Leu Leu Gln Val
Leu Leu Arg Ala
Leu Leu Val Lys
Leu Leu Val Gln
Leu Asn Ile Ile
Leu Asn Ile Leu
Leu Asn Leu Ile
Leu Asn Leu Leu
Leu Pro Asp Lys
Leu Pro Lys Asp
Leu Pro Arg Ser
Leu Pro Ser Arg
Leu Gln Ile Val
Leu Gln Leu Val
Leu Gln Val Ile
Leu Gln Val Leu
Leu Arg Ala Ile
Leu Arg Ala Leu
Leu Arg Ile Ala
Leu Arg Leu Ala
Leu Arg Pro Ser
Leu Arg Ser Pro
Leu Ser Pro Arg
Leu Ser Arg Pro
Leu Val Ile Lys
Leu Val Ile Gln
Leu Val Lys Ile
Leu Val Lys Leu
Leu Val Leu Lys
Leu Val Leu Gln
Leu Val Gln Ile
Leu Val Gln Leu
Asn Ile Ile Ile
Asn Ile Ile Leu
Asn Ile Leu Ile
Asn Ile Leu Leu
Asn Leu Ile Ile
Asn Leu Ile Leu
Asn Leu Leu Ile
Asn Leu Leu Leu
Pro Asp Ile Lys
Pro Asp Lys Ile
Pro Asp Lys Leu
Pro Asp Leu Lys
Pro Glu Lys Val
Pro Glu Val Lys
Pro Ile Asp Lys
Pro Ile Lys Asp
Pro Ile Arg Ser
Pro Ile Ser Arg
Pro Lys Asp Ile
Pro Lys Asp Leu
Pro Lys Glu Val
Pro Lys Ile Asp
Pro Lys Leu Asp
Pro Lys Val Glu
Pro Leu Asp Lys
Pro Leu Lys Asp
Pro Leu Arg Ser
Pro Leu Ser Arg
Pro Arg Ile Ser
Pro Arg Leu Ser
Pro Arg Ser Ile
Pro Arg Ser Leu
Pro Arg Thr Val
Pro Arg Val Thr
Pro Ser Ile Arg
Pro Ser Leu Arg
Pro Ser Arg Ile
Pro Ser Arg Leu
Pro Thr Arg Val
Pro Thr Val Arg
Pro Val Glu Lys
Pro Val Lys Glu
Pro Val Arg Thr
Pro Val Thr Arg
Gln Ile Ile Val
Gln Ile Leu Val
Gln Ile Val Ile
Gln Ile Val Leu
Gln Leu Ile Val
Gln Leu Leu Val
Gln Leu Val Ile
Gln Leu Val Leu
Gln Val Ile Ile
Gln Val Ile Leu
Gln Val Leu Ile
Gln Val Leu Leu
Arg Ala Ile Ile
Arg Ala Ile Leu
Arg Ala Leu Ile
Arg Ala Leu Leu
Arg Ile Ala Ile
Arg Ile Ala Leu
Arg Ile Ile Ala
Arg Ile Leu Ala
Arg Ile Pro Ser
Arg Ile Ser Pro
Arg Leu Ala Ile
Arg Leu Ala Leu
Arg Leu Ile Ala
Arg Leu Leu Ala
Arg Leu Pro Ser
Arg Leu Ser Pro
Arg Pro Ile Ser
Arg Pro Leu Ser
Arg Pro Ser Ile
Arg Pro Ser Leu
Arg Pro Thr Val
Arg Pro Val Thr
Arg Ser Ile Pro
Arg Ser Leu Pro
Arg Ser Pro Ile
Arg Ser Pro Leu
Arg Thr Pro Val
Arg Thr Val Pro
Arg Val Pro Thr
Arg Val Thr Pro
Arg Val Val Val
Ser Ile Pro Arg
Ser Ile Arg Pro
Ser Leu Pro Arg
Ser Leu Arg Pro
Ser Pro Ile Arg
Ser Pro Leu Arg
Ser Pro Arg Ile
Ser Pro Arg Leu
Ser Arg Ile Pro
Ser Arg Leu Pro
Ser Arg Pro Ile
Ser Arg Pro Leu
Thr Pro Arg Val
Thr Pro Val Arg
Thr Arg Pro Val
Thr Arg Val Pro
Thr Val Pro Arg
Thr Val Arg Pro
Val Glu Lys Pro
Val Glu Pro Lys
Val Ile Ile Lys
Val Ile Ile Gln
Val Ile Lys Ile
Val Ile Lys Leu
Val Ile Leu Lys
Val Ile Leu Gln
Val Ile Gln Ile
Val Ile Gln Leu
Val Lys Glu Pro
Val Lys Ile Ile
Val Lys Ile Leu
Val Lys Leu Ile
Val Lys Leu Leu
Val Lys Pro Glu
Val Leu Ile Lys
Val Leu Ile Gln
Val Leu Lys Ile
Val Leu Lys Leu
Val Leu Leu Lys
Val Leu Leu Gln
Val Leu Gln Ile
Val Leu Gln Leu
Val Pro Glu Lys
Val Pro Lys Glu
Val Pro Arg Thr
Val Pro Thr Arg
Val Gln Ile Ile
Val Gln Ile Leu
Val Gln Leu Ile
Val Gln Leu Leu
Val Arg Pro Thr
Val Arg Thr Pro
Val Arg Val Val
Val Thr Pro Arg
Val Thr Arg Pro
Val Val Arg Val
Val Val Val Arg
bis(2-ethylhexyl) hydrogen phosphate, compound with 2,2,2-nitrilotriethanol (1:1)
Sodium glycochenodeoxycholate
A bile acid salt that is the sodium salt of glycochenodeoxycholic acid. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) induces hepatocyte apoptosis[1][2].
Hederagenin(1-)
A monocarboxylic acid anion that is the conjugate base of hederagenin, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(10E,15Z)-9,12,13-Trihydroxyoctadeca-10,15-dienoylcarnitine
[3-carboxy-2-[(Z)-10-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(Z)-9-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium
Sodium glycodeoxycholate
A bile acid salt that is the sodium salt of glycodeoxycholic acid.
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(4S,7R,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)triazol-1-yl]ethyl]oxan-3-yl]-3-piperidin-1-ylpropanamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)triazol-1-yl]ethyl]oxan-3-yl]-3-piperidin-1-ylpropanamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)triazol-1-yl]ethyl]oxan-3-yl]-3-piperidin-1-ylpropanamide
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[(4R,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[(4S,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(4-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
3beta-(Acetyloxy)-14-(methoxycarbonyl)-4,4,8alpha,12,16-pentamethyl-17-oxo-5beta,9beta,10alpha,13alpha-androsta-11,15-dien-15-olate
20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-6-oxo-1-N-propan-2-yl-7-[(E)-prop-1-enyl]-2-N-(2-pyrrolidin-1-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-6-oxo-1-N-propan-2-yl-7-[(E)-prop-1-enyl]-2-N-(2-pyrrolidin-1-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate
(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
(4E,8E,12E)-2-(decanoylamino)-3-hydroxypentadeca-4,8,12-triene-1-sulfonic acid
4-[3-acetyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
andrastin C(1-)
An enolate anion resulting from the deprotonation of the enol group of andrastin C. Major species at pH 7.3. Published in http://dx.doi.org/10.1016/j.tet.2013.07.029